Minnesota Obesity Falls As GLP-1 Use Surges

Minnesota’s adult obesity rate has dropped for the second year in a row, and the timing has everyone arguing over what, exactly, is doing the heavy lifting. Are the new GLP-1 weight-loss drugs driving the change, or are years of public-health work and lifestyle shifts finally showing up in the numbers? The statewide decline is modest but noticeable, and it is unfolding at the same time prescriptions for Ozempic, Wegovy, and Zepbound are becoming far more common. Policymakers now find themselves weighing pricey medications against long-term prevention that reaches far beyond clinic walls.

Data from the federal Behavioral Risk Factor Surveillance System show that just over 32% of Minnesota adults were obese in 2024, down from nearly 34% in 2022. According to reporting by the Star Tribune, Minnesota's Medicaid program saw gross spending on GLP-1 medications jump from roughly $20 million in 2019 to about $133 million in 2024. State survey leaders cautioned that a two-year dip is unusual but still within the survey’s margin of error, so any clean cause-and-effect story remains out of reach for now.

Who Can Get The Drugs And Who Pays

Coverage of GLP-1s for obesity varies widely by insurer and by state. A KFF analysis shows big growth in Medicaid GLP-1 prescriptions and gross spending since 2019 and notes that most states that do cover the drugs use utilization controls such as prior authorization and BMI thresholds. Those rules help explain why some Minnesotans get the drugs covered while others face full retail prices. That patchwork access has moved to the center of debates about fairness, budgets, and how far public programs should go in paying for weight-loss medications.

What The Science Says About Lasting Benefits

Clinical trials show large short-term weight loss with GLP-1 and dual-agonist drugs, but the long game is much murkier. The American Diabetes Association reports that "sudden discontinuation ... results in weight recurrence of one-half to two-thirds of the weight loss within 1 year" and recommends close follow-up and shared decision-making around long-term therapy. That reality is a big reason researchers and public-health officials say they need more real-world, long-term data to know whether sustained use of these drugs will actually drive down chronic-disease rates across an entire population.

Real People, Real Tradeoffs

The Star Tribune’s reporting puts human faces on the data. One Minnesotan told the paper she lost about 65 pounds and lowered her diabetes risk after starting injections. Another quit after two months because nausea and lack of appetite made the medication impossible to live with. Those stories line up with known side effects, including nausea, vomiting, and diarrhea, that Harvard Health lists as some of the most common reasons people stop treatment. Cost is another major sticking point. Patients without coverage can face four-figure monthly bills, even though discounts and rebate programs sometimes bring out-of-pocket costs down.

State Policy And Prevention Still Matter

Public-health leaders say that no matter how popular GLP-1 drugs become, prevention programs remain the backbone of any long-term strategy to reduce obesity. SHIP grants that pay for walking paths, community nutrition initiatives, and other local efforts are still part of the state’s core approach. The Minnesota Department of Health continues to maintain data and resources on obesity and community prevention work and to support local investments alongside clinical care. How the state balances payment for medications against funding for broad, equitable prevention will help determine whether this recent dip in obesity turns into a lasting public-health win.

For now, Minnesota’s lower obesity rate raises more questions than it answers. The drugs clearly appear to help many individual patients, but whether they explain the statewide change, and whether those gains will stick, is still an open question. Expect the tug-of-war over coverage, cost, and prevention to keep playing out in clinics, legislative hearings, and state budgets for years to come.